Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx a xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx zakázaných látek x xxxxx xxxxxxx xxx rok 2024 - Xxxxxxxxxxx standard Xxxxxxxxxxx úmluvy proti xxxxxxx xx xxxxxx.

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x prezident republiky xxxxxxxx listinu x xxxxxxx změn Xxxxxxx X Českou xxxxxxxxxx.

Xxxx xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x souladu s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, pro Xxxxxx republiku xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x nahradilo Xxxxxxx X xxx xxx 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx vstoupila x xxxxxxxx xxx Českou xxxxxxxxx dne 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X pro xxx 2024 a xxxx xxxxxxx xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. XXXx. Xxxxxx, Xx.X., XX.X., x. r.

vrchní xxxxxxx xxxxx právní a xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Překlad xxxxxxxxxxx smlouvy do xxxxxxx jazyka

Úvod

Seznam zakázaných xxxxx x xxxxx xxxxxxx xx povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx každoročně xxxxxxxxxxxx xx rozsáhlém xxxxxxxxxxxx procesu xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.

Oficiální xxxx Xxxxxxx zakázaných xxxxx x xxxxx bude xxxxxxxxx XXXX x xxxx publikován x xxxxxxxxxx x francouzštině. X případě xxxxxxxxxxx xxxxxxxxxxxxx mezi anglickým x francouzským xxxxxx xxxxxxxxx znění v xxxxxxxxxx.

Xxxx xxxx uvedeny xxxxxxx xxxxx používané x tomto Xxxxxxx xxxxxxxxxx látek a xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX xxx daný xxxxx xxxxxxxxxxx xxxx xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx začínajícím xxxxx xxxx půlnocí (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, které xx xx Xxxxxxxxx xxxxxxxxx, xx xx konce Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, že xxxx xxxxx xxxx metoda xx xxxxxxxx Xxx xxxxxxx i Xxxx xxxxxx, xxx je xxxxxxxxxx x Kodexu.

Specifické x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Světového antidopingového Xxxxxx „pro účely xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Zakázané xxxxx Specifickými xxxxxxx, x xxxxxxxx těch xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Xxxxx Xxxxxxxx metoda nebude Xxxxxxxxxxx xxxxxxx, pokud xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx jako Xxxxxxxxxx xxxxxx.“ Podle xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx a Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxx xx xxxx důležité xxxx méně xxxxxxxxxx xxx jiné dopingové xxxxx nebo metody. Xxx spíše x xxxxx a metody, xxxxx Xxxxxxxxx pravděpodobně xxxx nebo použil x xxxxxx účelu xxx xx zlepšení xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx látky, xxxxx xxxx xxxx xxxxxx označeny x xxxxxx xxxxxx častého xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx sportu. Xxxx Xxxxxxxx látky xxxx označovány tyto xxxxx: xxxxxx, diamorfin (xxxxxx), methylendioxymetamfetamin (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 NESCHVÁLENÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Jakákoliv xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx xxxxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx není x xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx x xxxx (např. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj byl xxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx xxxxx xxx veterinární použití), xx xxxxxxxx xxxxx.

Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, mimo xxxx XXX-157, 2,4-dinitrofenol (XXX) x xxxxxxxxxx xxxxxxxxx (např. Reldesemtiv x Tirasemtiv).

S1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-hydroxy-5a-androst-1-en-17-on)		•	gestrinon
•	1-epiandrosteron (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (androst-4-en-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on)
•	7-keto-DHEA		•	metylklostebol
•	11ß-metyl-19-nortestosteron		•	metyldienolon (17β-hydroxy-17α-metylestra-4,9-dien-3-on)
•	17ɑ-methylepithiostanol (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (metyltrienolon, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on)
•	Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-hydroxy-5ɑ-androstan-3-on)		•	nandrolon (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on)		•	prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		&xxxx;•	xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx biologickými xxxxxx.

X1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, osilodrostat, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [SARM, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), LGD-4033 (ligandrol), XXX140, S-23 x XX-11], xxxxxxx x xxxxxxxxxx.

X2 PEPTIDOVÉ XXXXXXX, XXXXXXX FAKTORY, PŘÍBUZNÉ XXXXX X XXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě jsou Xxxxxxxxxxxx látky.

Následující xxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (EPO) X LÁTKY OVLIVŇUJÍCÍ XXXXXXXXXXX

Xxxx xxxx včetně:

S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx na EPO, [xxxx. XXX-Xx, metoxypolyetylenglykol-epoetin xxxx (XXXX)]; EPO- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx vyvolávajícího xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; molidustat (BAY 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Inhibitory signalizace xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (TGF-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Xxxxxxxx xxxxxxxxx opravného xxxxxxxxx, xxxx. asialo XXX; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX XXXXXXX X XXXXXX UVOLŇUJÍCÍ XXXXXXX

X2.2.1 Xxxxxxx stimulující xxxxxxxxxxx x mužů, xxxx xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (XX),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x jeho xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Kortikotropiny x xxxxxx xxxxxxxxxx faktory, xxxx. kortikorelin a xxxxxxxxxxxxx.

X2.2.3 Růstový xxxxxx (XX), xxxx analogy x fragmenty, xxxx xxxx xxxxxx:

• analogy xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• fragmenty xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx jiné xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx hormon (GHRH) x jeho xxxxxxx, xxxx. CJC-1293, CJC-1295, xxxxxxxxxx a xxxxxxxxxxx,

• xxxxxxxxxxx růstového hormonu (XXX) x xxxxxx xxxxxxxx [xxxx. anamorelin, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx XX (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), GHRP-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx jiné xxxxxx:

• xxxxxxxxxxxxx xxxxxxx faktory (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (HGF)

• růstový xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x jeho xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF)

• thymosin-β4 x xxxx xxxxxxxx, xxxx. TB-500

• vaskulárně-endoteliární xxxxxxx faktor (VEGF)

a xxxxx růstové faktory xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx svalech, xxxxxxxx xxxx vazech, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 BETA-2 XXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx beta-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx jsou xxxxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx salbutamol: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx dávkách, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 hodin xx xxxxxxxxx dávce;

• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 mikrogramů xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx látky a xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx důsledkem xxxxxxxxxxxx xxxxx (inhalační) xx xx výše xxxxxxx maximální xxxxx.

X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx S4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx xx xxxx X4.3 a X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx hormonové x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-ol)		•	androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX LÁTKY [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX ESTROGENOVÝCH RECEPTORŮ (XXXXX)]

Xxxx xxxx včetně:

•	arformoterol		•	indakaterol		•	reproterol		•	tretoquinol (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, např.:
•	konkurenty xxxxxxxxx xxxxxxxx XXX, např.:			- xxxxx xxxxxxxxx xxxx xxxxxx expresi xxxxxxxxxx
	- xxxxxxx receptory xxxxxxxx (xxxx. XXX-031)			- xxxxxxxx xxxxxx xxxxxxxxx (např. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx)
•	xxxxxxxxxx xxxxx receptoru xxxxxxxx XXX (např. bimagrumab)			- xxxxxxxxxx xxxxxxxxxxxxxx myostatin xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, domagro zumab, xxxxxxxxxxxxx, stamulumab)

S4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) xxxxxxxx xxxxxx (GW1516, GW501516) x xxxxxxxx Rev-erbɑ , např. SR9009, XX9011

X4.4.2 xxxxxxxx a xxxxxxxx insulinů

S4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX LÁTKY

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx a xxxxxxxxx látky, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. d- x x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx např.:

acetazolamid; xxxxxxxx; xxxxxxxxx; kanrenon; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, xxxx. bendroflumethiazid, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Plazmatické expandéry xxxxxxxx intravenózně, xxxx.:

xxxxxxx, xxxxxxx, hydroxyetyl xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x lokální xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. dorzolamid, brinzolamid);

• xxxxxxx xxxxxx felypresinu x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: u formoterolu, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx inhibitoru xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx felypresinu x xxxxxxxx anestezii), xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález (AAF), xxxxx Sportovec xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx metody x xxxx xxxxx jsou Xxxxxxxxxxxx s výjimkou xxxxx x X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. MANIPULACE S XXXX A KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, allogenní (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x registrovaném xxxxxxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, přenosu nebo xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx produkty, např. xxxxxx náhražky xx xxxx hemoglobinu x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.

M1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx nebo chemickými xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X2.1. Podvádění xxxx Xxxxx x xxxxxx xx xxxxxx porušit xxxxxxxxx x platnost Xxxxxx odebraných xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Vzorku.

M2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx xxxxxx 100 xx xx 12 hodin xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx ošetření, xxxxxxxxxxxxx xxxxxxx nebo klinických xxxxxxxxxxxxxx vyšetření.

M3. GENOVÝ X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, které xxxxx xxxxxx xxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo jiné xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx přenosů xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ PŘI XXXXXXX

Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx x xxxxxxxx xxxxx xxxxxxxxx x X6.X, xxx xxxx Nespecifické xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: kokain x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- a x-, xxxx zakázána.

Stimulancia zahrnují:

S6.A: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, je Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, BMPEA)		•	famprofazon		•	oktopamin
•	3-metylhexan-2-amin (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin)		•	hydrafinil (xxxxxxxxx)		•	xxxxxxxxxxx x jeho xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-dimetylpentylamin, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx a xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx a ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (dimetylamfetamin)		•	metylendioxymetamfetamin		•	selegilin
•	efedrin3)		•	metylefedrin3)		•	sibutramin
•	epinefrin (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• klonidin;

• xxxxxxxx imidazolinu v xxxxxxx jejich xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx použití (xxxx. xxxxxxxxxx, klonazolin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xylometazolin) x stimulancia xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, včetně jejich xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 KANABINOIDY

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx zakázané xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Návykové xxxxx x xxxx sekci: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x syntetické xxxxxxxxxxx xxxx zakázané, xxxx.

• x xxxxxx (hašiš, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (např. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx acetonid
•	kortizon		•	hydrokortizon
•	deflazakort		•	metylprednisolon

POZNÁMKA

• Jiné xxxxxxx xxxxxx (včetně xxxxxxxxxxx a topického: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx zakázány, xxxxx se používají x rámci výrobcem xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx indikací.

P1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a xxx xx to xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• lyžování/snowboarding (XXX) – xxxxx na xxxxxx, xxxxxxxxxxx xxxxx / X-xxxxx x xxxxxxxxx X-xxxxx / xxx air

• automobilový xxxxx (XXX)

• xxxxxxxx xxxxxx (XXXX)* x xxxxxxxxxxxx volného potápění, xxxx harpunou x xxxxxxx na xxxx

• xxxxxxxx (všechny xxxxxxxxxx) (XXXX)

• xxxxx (XXX)

• xxxx (XXX)

• minigolf (XXX)

• střelba (XXXX, XXX)*

* zakázané xxxx Xxxx xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx č. 2

Znění xxxxxxxxxxx xxxxxxx v xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: je xxxxxxxx xxxxx xxx xxxxxxxxxxx x moči vyšší xxx 5 mikrogramů x 1 xx.

²⁾ xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx koncentraci v xxxx xxxxx xxx 150 mikrogramů v 1 xx.

³⁾ xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx koncentraci x xxxx vyšší xxx 10 mikrogramů x 1 xx.

⁴⁾ epinefrin (xxxxxxxxx): xxxx zakázáno xxxxxxx xxxxxxxx, např. xxxxx, oční, nebo xxxxxxxx podávání s xxxxxxxxx xxxxxxxxxx.

⁵⁾ bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx a xxxxxxxx: tyto látky xxxx zahrnuté do Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx předpis x. 19/2025 Xx. xxxxx xxxxxxxxx dnem 28.1.2024.

Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, pokud xx xxxx xxxxxx derogační xxxxx shora xxxxxxxxx xxxxxxxx předpisu